NDAORALTABLET, EXTENDED RELEASE
Approved
Dec 1943
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
DESOXYN (methamphetamine hydrochloride) by Hikma is 12. First approved in 1943.
Drug data last refreshed 5h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DESOXYN is a methamphetamine hydrochloride oral tablet approved in 1943 for treating attention-deficit hyperactivity disorder (ADHD). It is a non-catecholamine sympathomimetic amine that acts as a CNS stimulant by blocking the reuptake of norepinephrine and dopamine and increasing their release into the extraneuronal space. The exact therapeutic mechanism in ADHD remains incompletely understood.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), suggesting defensive positioning and smaller brand team focus on retention and compliance initiatives.
Mechanism of Action
12. CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in the treatment of ADHD is not known. 12.2 Pharmacodynamics Amphetamines block the reuptake of norepinephrine and dopamine…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DESOXYN offers limited growth trajectory but provides valuable experience in legacy product stewardship, controlled substance management, and niche market navigation. The role emphasizes regulatory compliance, physician relationship management, and defending market position against generic competition.
Worked on DESOXYN at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.